Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22472924 | 0.99 | MMP13 (0.36) | MMP13VNN1KDM4ENPC1RAB9A | |
| SCHEMBL22472926 | 0.88 | MAPK1 (0.43) | KMT2AALDH1A1MAPK1AOC3 | |
| SCHEMBL22472890 | 0.87 | MAPK1 (0.41) | VNN1KMT2AMAPK1AOC3 | |
| SCHEMBL22449321 | 0.85 | MMP13 (0.34) | MMP13VNN1KDM4ENPC1RAB9A | |
| SCHEMBL22449317 | 0.84 | MMP13 (0.34) | MMP13VNN1KDM4ENPC1RAB9A | |
| SCHEMBL22472935 | 0.75 | HPGD (0.47) | KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21597934 | 0.74 | MAPK1 (0.41) | KMT2AMAPK1 | |
| SCHEMBL10074405 | 0.74 | NPC1 (0.44) | MMP13VNN1NPC1RAB9AKMT2A | |
| SCHEMBL22449299 | 0.73 | MAPK1 (0.39) | KMT2AMAPK1AOC3 | |
| SCHEMBL27176059 | 0.72 | LTA4H (0.34) | VNN1KDM4ENPY5RKDM5AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | MMP13 4317/4885VNN1 2471/4885KDM4E 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.